Stock listing

NASDAQ:CALC CalciMedica, Inc. Stock

Home listing (NASDAQ) of CalciMedica, Inc.

Follow CalciMedica, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:CALC

$1.26 USD +0.09 (+7.7%)

Close on Nov 20, 2026

Past year -92.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.20 – $1.33 USDNov 20, 2026
Volume
86,246 sharesNov 20, 2026
Market cap
$8.69M USDAt the close on Nov 20, 2026 · price × 6.90M shares outstanding
52-week range
$1.00 – $36.00 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$117,397 USDMedian day 55,000 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
CalciMedica, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:CALC · Home$1.26 USD+0.09 (+7.7%)86,246$1.28$1.33$1.20$1.17Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CALC · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.26+0.09+7.7%$1.28$1.33$1.2086,246
$1.17-0.05-4.1%$1.19$1.22$1.1533,644
$1.22+0.03+2.5%$1.21$1.29$1.1917,320
$1.19-0.02-1.7%$1.27$1.30$1.1373,317
$1.21-0.01-0.8%$1.31$1.31$1.1930,708
$1.22-0.02-1.6%$1.289$1.402$1.1843,019
$1.24-0.13-9.5%$1.38$1.51$1.2490,177
$1.37-0.145-9.6%$1.52$1.52$1.3713,159
$1.515+0.155+11.4%$1.39$1.61$1.3989,532
$1.36+0.06+4.6%$1.28$1.36$1.2715,208
$1.30-0.045-3.3%$1.40$1.40$1.1624,025
$1.345-0.125-8.5%$1.44$1.44$1.3343,697
$1.47+0.07+5.0%$1.40$1.53$1.3851,081
$1.40-0.06-4.1%$1.74$1.75$1.34164,948
$1.46-0.29-16.6%$1.79$1.84$1.44105,100
$1.75+0.09+5.4%$1.83$1.83$1.53106,400
$1.66+0.35+26.7%$1.40$1.67$1.355211,500
$1.31+0.01+0.8%$1.26$1.35$1.2637,200
$1.30+0.07+5.7%$1.26$1.50$1.25157,600
$1.23+0.08+7.0%$1.19$1.35$1.16107,900
$1.150.000.0%$1.26$1.31$1.13123,400
$1.15+0.085+8.0%$1.10$1.20$1.07143,600
$1.065+0.045+4.4%$1.03$1.10$1.0241,900
$1.02-0.02-1.9%$1.03$1.083$1.0018,100
$1.04-0.04-3.7%$1.05$1.215$1.0413,500
$1.08+0.01+0.9%$1.08$1.152$1.0522,500
$1.07-0.05-4.5%$1.10$1.20$1.0341,200
$1.12-0.085-7.1%$1.22$1.23$1.08598,800
$1.205-0.065-5.1%$1.27$1.275$1.1974,900
$1.27-0.03-2.3%$1.299$1.34$1.2782,100
$1.30-0.18-12.2%$1.46$1.50$1.30221,300
$1.48-0.01-0.7%$1.485$1.49$1.467,700
$1.49-0.05-3.2%$1.53$1.61$1.42169,100
$1.54-0.06-3.8%$1.625$1.625$1.5326,600
$1.60-0.05-3.0%$1.64$1.70$1.5821,700
$1.65+0.03+1.9%$1.62$1.709$1.6025,800
$1.62+0.01+0.6%$1.67$1.67$1.6038,600
$1.61-0.07-4.2%$1.70$1.70$1.5843,100
$1.68-0.07-4.0%$1.75$1.75$1.6226,600
$1.75+0.01+0.6%$1.73$1.765$1.6240,800
$1.74-0.05-2.8%$1.81$1.81$1.7154,200
$1.79-0.08-4.3%$1.87$1.885$1.7665,400
$1.87+0.01+0.5%$1.93$1.979$1.7697,000
$1.86-0.06-3.1%$1.95$1.955$1.8650,400
$1.92-0.05-2.5%$1.98$1.998$1.9260,200
$1.97-0.01-0.5%$1.97$2.035$1.9298,700
$1.980.000.0%$1.995$2.06$1.9468,500
$1.98-0.02-1.0%$2.00$2.042$1.9455,000
$2.00+0.02+1.0%$1.97$2.02$1.87101,300
$1.98-0.14-6.6%$2.085$2.15$1.9623,200
$2.12-0.175-7.6%$2.22$2.29$2.0783,300
$2.295+0.275+13.6%$2.03$2.31$1.91181,600
$2.02-0.15-6.9%$2.11$2.15$1.992122,600
$2.17-0.03-1.4%$2.13$2.25$2.0994,100
$2.20+0.10+4.8%$2.115$2.27$2.11594,600
$2.10+0.10+5.0%$2.02$2.215$2.02113,600
$2.00-0.14-6.5%$2.11$2.26$2.00140,300
$2.14-0.18-7.8%$2.30$2.473$2.13165,100
$2.32-0.03-1.3%$2.33$2.38$2.2027,032
$2.35-0.59-20.1%$2.65$2.75$2.33559,620
$2.940.000.0%$3.00$3.00$2.8657,088
$2.94+0.16+5.8%$2.755$2.945$2.7358,748
$2.78-0.085-3.0%$2.90$2.995$2.759,968
$2.865-0.05-1.7%$2.965$3.00$2.80510,864
$2.915-0.15-4.9%$3.08$3.15$2.8543,500

Splits

1 split · NASDAQ:CALC · every price before a split is adjusted for it

DayRatioWhat
1-for-5Consolidation
Ticker
NASDAQ:CALC
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All CalciMedica, Inc. news

CalciMedica, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
11 in the last 12 months · 58 in all · newest Nov 10, 2026 · oldest 2023
Decks
8 decks · latest November 2026

Where CalciMedica, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:CALC · Home listing · This pageNASDAQUnited StatesUSD
BOATS:CALCBOATSUnited StatesUSD

Valuation

Price/book 2.1× against a median of 1.3×: 5th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$1.82M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
2.1×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
1.6×
Beta vs S&P 500
0.54

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
CalciMedica, Inc. · NASDAQ:CALCUS$8.69MUS$1.82Mn/an/an/a2.1×n/a1.6×0.54
Rapid Dose Therapeutics Corp · CSE:DOSEUS$9.13MUS$9.12Mn/a5.1×n/an/a−123.1%n/a0.64
CytoMed Therapeutics Limited · NASDAQ:GDTCUS$9.01MUS$8.23Mn/a14.7×n/a2.3×−730.3%0.1×0.16
PreveCeutical Medical Inc · CSE:PREVUS$8.97MUS$8.95Mn/an/an/an/an/an/a0.73
BioLineRX Ltd. · TASE:BLRXUS$8.90MUS$10.13Mn/a8.6×n/a0.5×−171.7%0.3×n/a
Active Biotech AB · OMXSTO:ACTIUS$8.67MUS$4.38Mn/an/an/a2.4×n/a0.0×n/a
BioVie Inc. · NASDAQ:BIVIUS$8.58MUS$1.10Mn/an/an/a1.3×n/a0.0×1.84
Vyome Holdings, Inc. · NASDAQ:HINDUS$8.42MUS$1.82Mn/a11.9×n/a1.3×n/a0.1×1.34
CRISM Therapeutics Corporation · LSE:CRTXUS$8.34MUS$5.37Mn/a17.8×n/a2.5×−823.8%0.0×n/a
Brainstorm Cell Therapeutics Inc. · OTC:BCLIUS$8.31MUS$10.08Mn/an/an/an/an/an/a0.40
Quantum Biopharma Ltd. Subordinate Voting Shares Class B · NASDAQ:QNTMUS$8.29M−US$3.20Mn/an/an/a0.7×n/a0.1×1.05
Median of the othersUS$8.63MUS$6.80M11.9×1.3×−451.0%0.1×0.73

Forecasts

3 strong buy · 1 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
38.00 USD · Analysts' mean
EPS, year to Dec 2026
-3.02 · 3 analysts

Team and board

Officers

OfficerRole
A. Rachel LehenyChief Executive Officer
Stephen BardinChief Financial Officer
Michael J. DunnPresident & Chief Operating Officer
John M. DunnGeneral Counsel
Stacey RuizSenior Vice President, Clinical Development
Eric W. RobertsChief Business Officer & Vice Chairman of the Board
Kenneth A. StaudermanChief Scientific Officer
Sudarshan HebbarChief Medical Officer

Board

DirectorRole
Bob WilsonChairman of the Board
A. Rachel LehenyChief Executive Officer
Alan GlicklichDirector
Allan L. ShawDirector
Eric W. RobertsChief Business Officer & Vice Chairman of the Board
Evgeny ZaytsevDirector
Fred GuerardDirector

Events

QuarterResultsShare move
Q3 2026Nov 10, 2026 · Before open−9.6%
Q2 2026Aug 11, 2026 · Before open−0.1%
Q1 2026May 12, 2026 · Before open+6.6%
Q4 2025Mar 3, 2026+23.1%
Q3 2025Nov 12, 2025 · Before open+4.0%
Q2 2025Aug 12, 2025 · Before open−10.1%
Q1 2025May 14, 2025 · Before open−0.9%
Q4 2024Mar 26, 2025 · Before open−2.9%
Q3 2024Nov 13, 2024 · Before open−2.6%
Q2 2024Aug 12, 2024 · After close−3.6%
All 20 quarters
QuarterResultsShare move
Q1 2024May 13, 2024 · After close+6.7%
Q4 2023Mar 28, 2024 · Before open−0.7%
Q3 2023Nov 9, 2023 · After close+7.1%
Q2 2023Aug 10, 2023 · After close−0.4%
Q1 2023May 12, 2023 · After close−0.4%
Q4 2022Mar 9, 2023 · Before open−6.8%
Q3 2022Nov 10, 2022 · After close−3.0%
Q2 2022Aug 11, 2022 · Before open−1.0%
Q1 2022May 10, 2022 · After close−6.8%
Q4 2021Mar 10, 2022 · Before open−3.9%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck26 slidesNovember 2026
Investor Presentation (June 2026)Investor deck29 slidesJun 24, 2026
Investor Presentation (October 2024)Investor deck38 slidesOct 30, 2024
American College of Gastroenterology (ACG) 2024 Annual Scientific MeetingConference13 slidesOctober 2024
Technical Presentation (June 2024)Technical14 slidesJun 27, 2024
Investor Presentation (February 2024)Investor deck31 slidesFeb 13, 2024
Investor Presentation (June 2023)Investor deck29 slidesJun 15, 2023
Merger or Acquisition (November 2022)Merger or acquisition23 slidesNov 22, 2022

Open Decks

Financings

RaiseDate
Private placement of units of common stock or pre-funded warrants with Series A and Series B warrant rights
Announced: US$15M–US$49M · US$0.8033 a unit · a right to receive one Series A warrant exercisable at $0.8033 per share and one… · Guggenheim Securities, LLC
Dealers: Guggenheim Securities, LLC (lead)
Insiders: Members of the Board of Directors and management team participate, priced at or above the Nasdaq Consolidated Closing Bid Price as of June 23, 2026
Use of proceeds: Pulmonary hypertension program: Phase 1b study of Auxora in PAH, IND-enabling work for CM5480, and general corporate purposes
Jun 24, 2026

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as GRAYBUG VISION, INC. Priced at US$16.00 a share on Sep 24, 2020.

Price
US$16.00 a share
Shares offered
5,625,000 shares of common stock
Offering size
US$90 million
Underwriters' option
Up to 843,750 more shares
Underwriters
SVB Leerink, Piper Sandler, Needham & Company, Wedbush PacGrow · In the order on the cover
Shares delivered
On or about Sep 29, 2020

Steps

StepWhen
Draft sent to the SEC in confidenceJul 31, 2020
Filed publiclySep 4, 2020
Amended onceSep 21, 2020
Shares registered with an exchangeSep 21, 2020
Declared effective by the SECSep 24, 2020
Final prospectus, with the priceSep 25, 2020

Open IPO · From the cover of the final prospectus (424B4) filed Sep 25, 2020

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue0000000
Cost of revenue46.0K58.0K58.0K52.0K519.0K395.0K303.0K175.0K
Gross profit-46.0K-58.0K-58.0K-52.0K-519.0K-395.0K-303.0K-175.0K
Research and development15.2M14.5M15.9M8.35M18.9M21.0M30.6M23.0M
Selling, general and administrative7.89M9.73M22.2M5.84M17.0M8.87M6.92M5.60M
Operating income-23.1M-24.2M-38.1M-14.2M-35.9M-29.8M-37.5M-28.6M
Depreciation and amortization46.0K58.0K58.0K52.0K519.0K395.0K303.0K175.0K
EBITDA-23.1M-24.1M-38.0M-14.1M-35.4M-29.4M-37.2M-28.4M
Interest expense1.42M0110.0K132.0K126.0K143.0K
Income before tax-29.6M-13.7M-34.4M-7.82M-35.8M-27.5M-37.0M-28.4M
Income tax001.00K1.00K-2.00M-538.0K-393.0K13.9K
Net income-29.6M-13.7M-34.4M-7.82M-35.8M-27.5M-37.0M-28.4M
Earnings per share, basic-1.97-1.22-7.66-111.16-1.69-5.25-33.41-165.51
Earnings per share, diluted-1.97-1.22-7.66-111.16-1.69-5.25-33.41

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents11.5M7.93M5.53M1.33M13.4M33.4M15.9M12.8M
Short-term investments1.50M10.7M5.71M050.3M61.6M20.1M
Receivables39.0K21.0K
Inventory-39.0K-21.0K
Current assets13.5M19.7M11.6M1.73M67.1M99.2M36.3M13.4M
Property, plant and equipment50.0K119.0K167.0K147.0K1.98M1.95M1.98M
Total assets13.6M19.8M12.2M3.35M69.1M101.8M40.7M17.8M
Accounts payable1.16M2.00M1.42M2.87M527.0K2.51M4.64M2.52M
Current liabilities3.78M3.68M4.03M4.78M4.06M7.00M12.3M5.79M
Long-term debt8.45M5.16M
Total debt9.70M5.36M131.4M78.8M
Total liabilities20.2M5.38M4.03M12.6M4.07M7.01M12.3M5.79M
Shareholders' equity-6.64M14.4M8.16M-71.3M-64.0M94.8M-103.0M12.0M
Shares outstanding3.09M13.5M5.75M84.2K21.4M21.0M1.37M171.5K

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations-21.2M-21.1M-25.7M-11.8M-31.5M-32.1M-31.2M-28.2M
Capital spending-28.0K-8.00K-78.0K-4.00K-488.0K-1.02M-605.0K-1.46M
Free cash flow-21.2M-21.2M-25.8M-11.8M-32.0M-33.1M-31.8M-29.7M
Cash from investing9.55M-4.42M8.88M-4.00K10.8M-42.6M-20.6M-1.46M
Cash from financing15.2M28.0M20.9M8.48M695.0K92.2M54.9M42.0M
Share buybacks-45.0K
Change in cash3.58M2.40M4.05M-3.29M-20.1M17.5M3.04M12.3M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 19, 2026Insider tradeSEC
3 · Initial statement of ownershipNov 19, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 10, 2026Quarterly reportSEC
8-K · Current reportNov 10, 2026ResultsSEC
4 · Change in ownershipNov 5, 2026Insider tradeSEC
8-K · Current reportOct 16, 2026Management or board changeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipOct 5, 2026Insider tradeSEC
4 · Change in ownershipOct 5, 2026Insider tradeSEC
4 · Change in ownershipOct 5, 2026Insider tradeSEC
4 · Change in ownershipOct 5, 2026Insider tradeSEC
4 · Change in ownershipOct 5, 2026Insider tradeSEC
8-K · Current reportSep 30, 2026Current reportSEC
424B5 · ProspectusSep 30, 2026Offer documentSEC
4 · Change in ownershipSep 28, 2026Insider tradeSEC
4 · Change in ownershipSep 28, 2026Insider tradeSEC
4 · Change in ownershipSep 28, 2026Insider tradeSEC
4 · Change in ownershipSep 28, 2026Insider tradeSEC
S-8 · Registration statement for employee plansSep 23, 2026Offer documentSEC
8-K · Current reportSep 16, 2026Current reportSEC
8-K · Current reportSep 2, 2026Current reportSEC
8-K · Current reportAug 27, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeAug 25, 2026Big-stake noticeSEC
4 · Change in ownershipAug 24, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 24, 2026Big-stake noticeSEC
4 · Change in ownershipAug 21, 2026Insider tradeSEC
4 · Change in ownershipAug 21, 2026Insider tradeSEC
4 · Change in ownershipAug 21, 2026Insider tradeSEC
4 · Change in ownershipAug 21, 2026Insider tradeSEC
4 · Change in ownershipAug 21, 2026Insider tradeSEC
4 · Change in ownershipAug 21, 2026Insider tradeSEC
4 · Change in ownershipAug 21, 2026Insider tradeSEC
4 · Change in ownershipAug 21, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 21, 2026Big-stake noticeSEC
8-K · Current reportAug 19, 2026Management or board changeSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 11, 2026Quarterly reportSEC
8-K · Current reportAug 11, 2026ResultsSEC
EFFECT · Notice that a registration is effectiveAug 3, 2026Other filingsSEC
S-3 · Registration statementJul 24, 2026Offer documentSEC
ARS · Annual report to shareholdersJul 23, 2026Annual reportSEC
DEF 14A · Proxy statementJul 23, 2026Meeting noticeSEC
SCHEDULE 13G · Big-stake noticeJul 20, 2026Big-stake noticeSEC
PRE 14A · Preliminary proxy statementJul 13, 2026Meeting noticeSEC
3 · Initial statement of ownershipJul 10, 2026Insider tradeSEC
SCHEDULE 13D · Big-stake noticeJul 10, 2026Big-stake noticeSEC
4 · Change in ownershipJul 7, 2026Insider tradeSEC
3 · Initial statement of ownershipJul 7, 2026Insider tradeSEC
8-K · Current reportJul 7, 2026Management or board changeSEC
SCHEDULE 13D · Big-stake noticeJul 2, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJun 30, 2026Big-stake noticeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJun 25, 2026Big-stake noticeSEC
8-K · Current reportJun 24, 2026Material contractSEC
8-K · Current reportJun 24, 2026Material contractSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 20, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 12, 2026Quarterly reportSEC
8-K · Current reportMay 12, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 8, 2026Big-stake noticeSEC
10-K/A · Annual report, amendedApr 30, 2026Annual reportSEC
4 · Change in ownershipApr 7, 2026Insider tradeSEC
4 · Change in ownershipApr 7, 2026Insider tradeSEC
4 · Change in ownershipApr 7, 2026Insider tradeSEC
4 · Change in ownershipApr 7, 2026Insider tradeSEC
4 · Change in ownershipApr 7, 2026Insider tradeSEC
4 · Change in ownershipApr 7, 2026Insider tradeSEC
8-K · Current reportMar 18, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveMar 12, 2026Other filingsSEC
CORRESP · Letter to the SECMar 9, 2026Other filingsSEC
UPLOAD · Letter from the SECMar 6, 2026Other filingsSEC
S-3 · Registration statementMar 3, 2026Offer documentSEC
10-K · Annual reportMar 3, 2026Annual reportSEC
8-K · Current reportMar 3, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 6, 2026Big-stake noticeSEC
8-K · Current reportJan 28, 2026Current reportSEC
8-K · Current reportJan 28, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeDec 1, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2025Quarterly reportSEC
8-K · Current reportNov 12, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 7, 2025Big-stake noticeSEC
8-K · Current reportNov 6, 2025Current reportSEC
424B5 · ProspectusNov 6, 2025Offer documentSEC
SCHEDULE 13G · Big-stake noticeOct 29, 2025Big-stake noticeSEC
4 · Change in ownershipOct 14, 2025Insider tradeSEC
4 · Change in ownershipSep 22, 2025Insider tradeSEC
4 · Change in ownershipSep 17, 2025Insider tradeSEC
4 · Change in ownershipSep 15, 2025Insider tradeSEC
4 · Change in ownershipSep 11, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedSep 9, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedSep 2, 2025Big-stake noticeSEC
4 · Change in ownershipSep 2, 2025Insider tradeSEC
4 · Change in ownershipAug 25, 2025Insider tradeSEC
4 · Change in ownershipAug 21, 2025Insider tradeSEC
4 · Change in ownershipAug 21, 2025Insider tradeSEC
4 · Change in ownershipAug 19, 2025Insider tradeSEC
4 · Change in ownershipAug 18, 2025Insider tradeSEC
10-Q · Quarterly reportAug 12, 2025Quarterly reportSEC
8-K · Current reportAug 12, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 5, 2025Big-stake noticeSEC
4 · Change in ownershipJul 29, 2025Insider tradeSEC
4 · Change in ownershipJul 23, 2025Insider tradeSEC
4 · Change in ownershipJul 22, 2025Insider tradeSEC
4 · Change in ownershipJul 21, 2025Insider tradeSEC
4 · Change in ownershipJul 18, 2025Insider tradeSEC
4 · Change in ownershipJul 18, 2025Insider tradeSEC
4 · Change in ownershipJul 16, 2025Insider tradeSEC
4 · Change in ownershipJul 15, 2025Insider tradeSEC
4 · Change in ownershipJul 10, 2025Insider tradeSEC
4 · Change in ownershipJul 2, 2025Insider tradeSEC
4 · Change in ownershipJun 27, 2025Insider tradeSEC
S-8 POSJun 27, 2025Offer documentSEC
8-K · Current reportJun 27, 2025Management or board changeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
S-8 · Registration statement for employee plansJun 24, 2025Offer documentSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
DEFA14A · Additional proxy materialJun 9, 2025Meeting noticeSEC
8-K · Current reportJun 6, 2025Current reportSEC
4 · Change in ownershipJun 3, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeMay 28, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 14, 2025Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 14, 2025Big-stake noticeSEC
8-K · Current reportMay 14, 2025ResultsSEC
ARS · Annual report to shareholdersApr 29, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 29, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2025Meeting noticeSEC
4 · Change in ownershipApr 25, 2025Insider tradeSEC
4 · Change in ownershipApr 25, 2025Insider tradeSEC
4 · Change in ownershipApr 25, 2025Insider tradeSEC
4 · Change in ownershipApr 25, 2025Insider tradeSEC
4 · Change in ownershipApr 25, 2025Insider tradeSEC
4 · Change in ownershipApr 25, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeApr 1, 2025Big-stake noticeSEC
10-K · Annual reportMar 27, 2025Annual reportSEC
8-K · Current reportMar 27, 2025ResultsSEC
8-K · Current reportMar 5, 2025Material contractSEC
8-K · Current reportMar 4, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 3, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
4 · Change in ownershipJan 16, 2025Insider tradeSEC
3 · Initial statement of ownershipJan 16, 2025Insider tradeSEC
8-K · Current reportJan 14, 2025Management or board changeSEC
8-K · Current reportDec 20, 2024Current reportSEC
424B5 · ProspectusDec 20, 2024Offer documentSEC
SCHEDULE 13G · Big-stake noticeDec 13, 2024Big-stake noticeSEC
4 · Change in ownershipDec 6, 2024Insider tradeSEC
SC 13D · Big-stake noticeNov 26, 2024Big-stake noticeSEC
3 · Initial statement of ownershipNov 15, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 13, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 13, 2024Quarterly reportSEC
8-K · Current reportNov 13, 2024ResultsSEC
8-K · Current reportNov 8, 2024Management or board changeSEC
4/A · Change in ownership, amendedNov 6, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedNov 6, 2024Big-stake noticeSEC
4 · Change in ownershipNov 5, 2024Insider tradeSEC
4 · Change in ownershipNov 5, 2024Insider tradeSEC
4 · Change in ownershipNov 1, 2024Insider tradeSEC
4 · Change in ownershipNov 1, 2024Insider tradeSEC
4 · Change in ownershipNov 1, 2024Insider tradeSEC
8-K · Current reportOct 31, 2024Material contractSEC
424B5 · ProspectusOct 31, 2024Offer documentSEC
424B5 · ProspectusOct 30, 2024Offer documentSEC
8-K · Current reportOct 30, 2024ResultsSEC
8-K · Current reportOct 30, 2024Current reportSEC
4 · Change in ownershipSep 11, 2024Insider tradeSEC
4 · Change in ownershipAug 28, 2024Insider tradeSEC
4 · Change in ownershipAug 28, 2024Insider tradeSEC
4 · Change in ownershipAug 28, 2024Insider tradeSEC
4 · Change in ownershipAug 28, 2024Insider tradeSEC
4 · Change in ownershipAug 28, 2024Insider tradeSEC
4 · Change in ownershipAug 28, 2024Insider tradeSEC
4 · Change in ownershipAug 28, 2024Insider tradeSEC
4 · Change in ownershipAug 28, 2024Insider tradeSEC
4 · Change in ownershipAug 28, 2024Insider tradeSEC
4 · Change in ownershipAug 28, 2024Insider tradeSEC
4 · Change in ownershipAug 27, 2024Insider tradeSEC
S-8 · Registration statement for employee plansAug 27, 2024Offer documentSEC
8-K · Current reportAug 27, 2024Management or board changeSEC
4 · Change in ownershipAug 26, 2024Insider tradeSEC
4 · Change in ownershipAug 26, 2024Insider tradeSEC

This page holds 200 of 539 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from CalciMedica, Inc.’s releases · as of Nov 5, 2026

Common shares
6,895,149
Fully diluted
6,895,149

Fully diluted

LineSharesAs of
Common shares6,895,149Nov 5, 2026

Share count over time

CountShares
Nov 5, 20266,895,149
Sep 30, 20266,894,649
Aug 27, 2026

Open Cap table

Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Extended Market Index Fund88,9561.3%US$91,625Jun 30, 2026
Fidelity Extended Market Index Fund65,6820.95%US$53,662May 31, 2026
Fidelity Series Total Market Index Fund12,4210.18%US$10,148May 31, 2026
Fidelity Total Market Index Fund11,6860.17%US$9,547May 31, 2026
Fidelity Nasdaq Composite Index Fund9,6990.14%US$7,924May 31, 2026

Insider trades

TradeTradeSharesPriceValueDate
Middleton Fred A
Director, 10% owner
Buy248,972USD 0.80US$199KJun 25, 2026

Big stakes

StakeStakeSharesDateFiling
Alafi Capital Company LLC19.90%7.22MAug 19, 2026Schedule 13D
Bering Partners II GP, L.L.C.9.99%3.55MAug 19, 2026Schedule 13D
Armistice Capital, LLC9.99%3.41MJun 30, 2026Schedule 13G
Stonepine Capital Management, LLC8.10%580KSep 30, 2026Schedule 13G
Woodline Partners LP8.10%2.49MJun 30, 2026Schedule 13G
Eric W. Roberts6.40%1.97MJun 25, 2026Schedule 13D
CVI Investments, Inc.5.10%1.56MJun 23, 2026Schedule 13G
Avenue Venture Opportunities Fund II, L.P.4.99%4.64MJun 23, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Fred A Middleton
Other companies: Chimerix Inc (Director · Mar 28, 2018 – Apr 21, 2025 · Past); Stereotaxis, Inc. (Director · Jan 3, 2012 – Mar 2, 2018 · Past); Endocyte Inc (Director · Dec 16, 2011 – Dec 21, 2018 · Past); Pacira BioSciences, Inc. (Director · Nov 21, 2011 – Jun 21, 2013 · Past)
Director · Since at least Mar 20, 2023
Julia Marie Eastland
Other companies: Zentalis Pharmaceuticals, Inc. (CEO & President, Director · Since at least Nov 13, 2024); Lantheus Holdings, Inc. (Director · Since at least Sep 3, 2024); Dynavax Technologies Corporation (Director · May 28, 2021 – May 23, 2024 · Past); Harpoon Therapeutics Inc (President and CEO, Director · May 4, 2021 – Mar 11, 2024 · Past)
Director · Jun 2, 2021 – Mar 23, 2023 · Past
Robert N Wilson
Other companies: VIVUS Inc (Director · Apr 26, 2013 – Aug 14, 2013 · Past); Madrigal Pharmaceuticals, Inc. (Director · Feb 5, 2007 – Jul 1, 2015 · Past); Hess Corporation (Director · Jan 30, 2006 – Mar 1, 2016 · Past); Charles Schwab Corporation (the) (Director · Jan 3, 2006 – Dec 13, 2018 · Past)
Director · Since at least Mar 20, 2023
Christina Ackermann
Other companies: Verona Pharma plc (Director · Since at least Sep 1, 2023); Bausch + Lomb Corporation (Please see remarks · May 5, 2022 – Mar 1, 2023 · Past); Bausch Health Companies Inc. (EVP AND GENERAL COUNSEL · Aug 8, 2016 – Mar 10, 2022 · Past)
Director · Sep 24, 2020 – Mar 23, 2023 · Past
Daniel E Geffken
Other companies: ProMIS Neurosciences Inc. (Chief Financial Officer · Jul 7, 2022 – Oct 26, 2023 · Past); CERo Therapeutics Holdings, Inc. (Chief Financial Officer · Oct 5, 2021 – Feb 14, 2024 · Past); Windtree Therapeutics, Inc. (Director · Apr 24, 2019 – Aug 23, 2023 · Past)
Interim CFO · Mar 20, 2023 – May 17, 2024 · Past
Allan Shaw
Other companies: Onconetix, Inc. (Director · Feb 17, 2022 – Aug 19, 2022 · Past); VIVUS Inc (Director · Oct 15, 2017 – Oct 26, 2018 · Past)
Director · Since at least Mar 20, 2023
Christy L Shaffer
Other companies: G1 Therapeutics Inc (Director · May 16, 2017 – Nov 30, 2017 · Past); Clearside Biomedical Inc (Director · Jun 1, 2016 – Jun 20, 2024 · Past)
Director · Sep 24, 2020 – Mar 23, 2023 · Past
Eric W. Roberts
Other companies: VIVUS Inc (Director · Sep 15, 2015 – Feb 28, 2019 · Past); Invuity Inc (Director · Jun 11, 2015 – Oct 23, 2018 · Past)
Chief Business Officer & Vice Chairman of the Board · Since at least Mar 20, 2023
Gerald D Cagle
Other companies: Clearside Biomedical Inc (Director · Jun 1, 2016 – Jun 25, 2018 · Past); Aerie Pharmaceuticals Inc. (Director · Oct 25, 2013 – Jun 17, 2021 · Past)
Director · Sep 24, 2020 – Jun 2, 2021 · Past
Alan Glicklich
Other companies: Aduro Biotech Inc (Chief Medical Officer · Oct 5, 2020 – Feb 10, 2022 · Past)
Director · Since at least Jan 14, 2025
All 26 people
PersonSeat
A. Rachel Leheny
Other companies: Anthera Pharmaceuticals Inc (Director · Feb 23, 2010 – Sep 30, 2010 · Past)
Chief Executive Officer · Since at least Mar 20, 2023
Daniel Salain
Other companies: Aceragen Inc. (CHIEF OPERATING OFFICER · Sep 28, 2022 – Jan 20, 2023 · Past)
CTOO · Sep 24, 2020 – Dec 8, 2020 · Past
Evgeny Zaytsev
Other companies: Clearside Biomedical Inc (Director · Jun 1, 2016 – Jun 20, 2018 · Past)
Director · Since at least Jul 2, 2026
Frederic Guerard
Other companies: LENZ Therapeutics, Inc. (Chief Executive Officer · Since at least Mar 21, 2024)
Director · Since at least Sep 24, 2020
Hansoo Michael Keyoung
Other companies: Kairos Pharma, Ltd. (Director · Since at least Sep 16, 2024)
Director · Sep 24, 2020 – Sep 29, 2020 · Past
Allan L. ShawDirector · Since at least Nov 4, 2026
Bob WilsonChairman of the Board · Since at least Jun 29, 2026
Dirk SauerDirector · Apr 13, 2022 – Mar 23, 2023 · Past
Fred GuerardDirector · Since at least Nov 4, 2026
John M. DunnGeneral Counsel · Since at least Nov 4, 2026
Kenneth A. StaudermanChief Scientific Officer · Since at least Mar 20, 2023
Michael J. DunnPresident & Chief Operating Officer · Since at least Mar 20, 2023
Parisa ZamiriChief Medical Officer · Sep 24, 2020 – Mar 23, 2023 · Past
Stacey RuizSenior Vice President, Clinical Development · Since at least Nov 4, 2026
Stephen BardinChief Financial Officer · Since at least Nov 7, 2024
Sudarshan HebbarChief Medical Officer · Since at least Mar 20, 2023

Open People

Log in to ask 6ix AI your own questions about CalciMedica, Inc.